Hi hig0606,
APN01 patented by Apeiron Biologics is a legitimate candidate , it stops the Ace 2 receptor in the statified epithelium in the nose throat area from recognising the Covid 19 virus. Thus possibly reducing viral take up in the body.
But, the downside is that it is given intravenously with possibly three doses daily ( so does it work maybe, is it practical > No) . A tablet form is better for a World health solution.
Ann: PAA Evaluate MPL Suitability for Ex-Vivo Human COVID-19 Test, page-96
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.015(8.57%) |
Mkt cap ! $75.22M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 19.0¢ | 18.0¢ | $340.2K | 1.839M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 85126 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 159277 | 2 |
View Market Depth
| Last trade - 16.10pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
19.0¢ |
Change
0.015 ( 7.22 %) |
||||
| Open | High | Low | Volume | ||
| 18.0¢ | 19.0¢ | 18.0¢ | 1360996 | ||
| Last updated 15.51pm 14/05/2024 ? | |||||
| PAA (ASX) Chart |